SAN DIEGO, CA – September 10, 2026 (STL.News) Aardvark Therapeutics, Inc. (NASDAQ: AARD) is facing a federal securities class action lawsuit alleging that investors were misled about the safety and development prospects of its lead drug candidate, ARD-101, before clinical setbacks sent the biotechnology company’s shares sharply lower. The litigation comes as several securities law firms are notifying Aardvark investors of an Oct. 13, 2026, deadline to seek appointment as lead plaintiff. The class action was filed in the U.S. District Court for the Southern District of California and is docketed as 26-cv-04643. According to litigation notices, the action

Source: Read Original Article